S&P 500   4,230.72 (-1.34%)
DOW   33,050.25 (-1.15%)
QQQ   354.78 (-1.79%)
AAPL   171.91 (-1.06%)
MSFT   314.34 (-2.32%)
META   301.24 (-1.82%)
GOOGL   132.54 (-1.21%)
AMZN   125.30 (-3.21%)
TSLA   249.04 (-1.02%)
NVDA   437.32 (-2.34%)
NIO   8.69 (-1.14%)
BABA   84.78 (-2.02%)
AMD   100.42 (-2.76%)
T   14.61 (-0.41%)
F   12.11 (-1.62%)
MU   68.22 (+0.38%)
CGC   0.70 (-5.39%)
GE   107.42 (-1.26%)
DIS   79.67 (-2.45%)
AMC   7.95 (-2.45%)
PFE   33.88 (-0.18%)
PYPL   57.90 (-1.13%)
NFLX   378.56 (-0.47%)
S&P 500   4,230.72 (-1.34%)
DOW   33,050.25 (-1.15%)
QQQ   354.78 (-1.79%)
AAPL   171.91 (-1.06%)
MSFT   314.34 (-2.32%)
META   301.24 (-1.82%)
GOOGL   132.54 (-1.21%)
AMZN   125.30 (-3.21%)
TSLA   249.04 (-1.02%)
NVDA   437.32 (-2.34%)
NIO   8.69 (-1.14%)
BABA   84.78 (-2.02%)
AMD   100.42 (-2.76%)
T   14.61 (-0.41%)
F   12.11 (-1.62%)
MU   68.22 (+0.38%)
CGC   0.70 (-5.39%)
GE   107.42 (-1.26%)
DIS   79.67 (-2.45%)
AMC   7.95 (-2.45%)
PFE   33.88 (-0.18%)
PYPL   57.90 (-1.13%)
NFLX   378.56 (-0.47%)
S&P 500   4,230.72 (-1.34%)
DOW   33,050.25 (-1.15%)
QQQ   354.78 (-1.79%)
AAPL   171.91 (-1.06%)
MSFT   314.34 (-2.32%)
META   301.24 (-1.82%)
GOOGL   132.54 (-1.21%)
AMZN   125.30 (-3.21%)
TSLA   249.04 (-1.02%)
NVDA   437.32 (-2.34%)
NIO   8.69 (-1.14%)
BABA   84.78 (-2.02%)
AMD   100.42 (-2.76%)
T   14.61 (-0.41%)
F   12.11 (-1.62%)
MU   68.22 (+0.38%)
CGC   0.70 (-5.39%)
GE   107.42 (-1.26%)
DIS   79.67 (-2.45%)
AMC   7.95 (-2.45%)
PFE   33.88 (-0.18%)
PYPL   57.90 (-1.13%)
NFLX   378.56 (-0.47%)
S&P 500   4,230.72 (-1.34%)
DOW   33,050.25 (-1.15%)
QQQ   354.78 (-1.79%)
AAPL   171.91 (-1.06%)
MSFT   314.34 (-2.32%)
META   301.24 (-1.82%)
GOOGL   132.54 (-1.21%)
AMZN   125.30 (-3.21%)
TSLA   249.04 (-1.02%)
NVDA   437.32 (-2.34%)
NIO   8.69 (-1.14%)
BABA   84.78 (-2.02%)
AMD   100.42 (-2.76%)
T   14.61 (-0.41%)
F   12.11 (-1.62%)
MU   68.22 (+0.38%)
CGC   0.70 (-5.39%)
GE   107.42 (-1.26%)
DIS   79.67 (-2.45%)
AMC   7.95 (-2.45%)
PFE   33.88 (-0.18%)
PYPL   57.90 (-1.13%)
NFLX   378.56 (-0.47%)
NASDAQ:LMDX

LumiraDx (LMDX) Stock Forecast, Price & News

$0.20
-0.01 (-5.16%)
(As of 12:04 PM ET)
Compare
Today's Range
$0.20
▼
$0.21
50-Day Range
$0.22
▼
$0.46
52-Week Range
$0.20
▼
$1.61
Volume
365,347 shs
Average Volume
315,961 shs
Market Capitalization
$64.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.45
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

LumiraDx MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
625.0% Upside
$1.45 Price Target
Short Interest
Healthy
0.32% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.05mentions of LumiraDx in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.51) to ($0.29) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Medical Sector

638th out of 976 stocks

Pharmaceutical Preparations Industry

295th out of 451 stocks

See Top Rated MarketRank™ Stocks Here

LMDX stock logo

About LumiraDx (NASDAQ:LMDX) Stock

LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company is headquartered in London, the United Kingdom.

LMDX Price History

LMDX Stock News Headlines

September 27, 2023 | finance.yahoo.com
LumiraDx Limited (LMDX) Loses -25.54% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
September 21, 2023 | finance.yahoo.com
What Makes LumiraDx Limited (LMDX) a New Buy Stock
October 3, 2023 | Edge On The Street (Ad)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
August 27, 2023 | markets.businessinsider.com
BTIG Keeps Their Buy Rating on LumiraDx (LMDX)
August 27, 2023 | finance.yahoo.com
Earnings Update: LumiraDx Limited (NASDAQ:LMDX) Just Reported And Analysts Are Trimming Their Forecasts
August 25, 2023 | finance.yahoo.com
LumiraDx Limited (NASDAQ:LMDX) Q2 2023 Earnings Call Transcript
August 24, 2023 | finance.yahoo.com
LumiraDx Reports Second Quarter 2023 Results
August 24, 2023 | finance.yahoo.com
LumiraDx Limited (LMDX) Reports Q2 Loss, Misses Revenue Estimates
October 3, 2023 | Edge On The Street (Ad)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
August 21, 2023 | finance.yahoo.com
This LumiraDx Insider Increased Their Holding By 150% Last Year
August 16, 2023 | finance.yahoo.com
LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24
August 1, 2023 | benzinga.com
CapitalGainsReport Potential Breakouts Watchlist (SHGI, IQST, PHUN LMDX)
August 1, 2023 | finance.yahoo.com
Positive Sentiment Still Eludes LumiraDx Limited (NASDAQ:LMDX) Following 27% Share Price Slump
June 30, 2023 | markets.businessinsider.com
LumiraDx Submits Medical Device Application To FDA For COVID Ultra Test
June 30, 2023 | finance.yahoo.com
LumiraDx Submits First 510(k) Application to the FDA for COVID Ultra Test
June 21, 2023 | benzinga.com
LumiraDx shares are trading higher after the company received UK approval for its COVID Ultra and COVID & RSV Tests.
June 21, 2023 | msn.com
LumiraDX Skyrockets on Bagging Approval for COVID-19 and RSV Tests in the U.K.
June 21, 2023 | investorplace.com
Why Is LumiraDx (LMDX) Stock Up 30% Today?
June 20, 2023 | finance.yahoo.com
LumiraDx Receives UK CTDA Approval for COVID Ultra and COVID & RSV Tests
June 6, 2023 | ca.finance.yahoo.com
LMDX - LumiraDx Limited
May 18, 2023 | msn.com
Ladenburg Thalmann Maintains LumiraDx (LMDX) Buy Recommendation
May 18, 2023 | msn.com
Goldman Sachs Maintains LumiraDx (LMDX) Neutral Recommendation
May 17, 2023 | markets.businessinsider.com
The Latest Analyst Ratings for LumiraDx
May 17, 2023 | msn.com
Raymond James Maintains LumiraDx (LMDX) Outperform Recommendation
May 16, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: LumiraDx (LMDX) and Aerovate Therapeutics (AVTE)
May 16, 2023 | msn.com
LumiraDx: Q1 Earnings Insights
May 16, 2023 | finance.yahoo.com
LumiraDx Limited (LMDX) Reports Q1 Loss, Tops Revenue Estimates
See More Headlines
Receive LMDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LumiraDx and its competitors with MarketBeat's FREE daily newsletter.

LMDX Company Calendar

Last Earnings
8/24/2023
Today
10/03/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LMDX
CUSIP
N/A
CIK
1685428
Web
www.lumiradx.com
Phone
354-640-0540
Fax
N/A
Employees
1,210
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$1.45
High Stock Price Forecast
$2.70
Low Stock Price Forecast
$0.80
Forecasted Upside/Downside
+570.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.09)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-447,790,000.00
Net Margins
-268.45%
Pretax Margin
-264.58%
Return on Equity
N/A
Return on Assets
-77.95%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.97
Quick Ratio
1.01

Sales & Book Value

Annual Sales
$254.48 million
Price / Sales
0.27
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.33) per share
Price / Book
-0.66

Miscellaneous

Outstanding Shares
318,550,000
Free Float
205,749,000
Market Cap
$68.93 million
Optionable
Not Optionable
Beta
1.13
5G Stocks: The Path Forward is Profitable Cover
5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Ron Zwanziger (Age 69)
    Co-Founder, Chairman & CEO
  • Dr. David Scott Ph.D. (Age 66)
    Co-Founder, CTO & Director
  • Dr. Jerome F. McAleer Ph.D. (Age 67)
    Co-Founder, Chief Scientist & Director
  • Mr. Dorian LeBlanc CPA (Age 48)
    CFO & VP of Global Operations
  • Ms. Veronique Ameye Esq. (Age 46)
    M.B.A., Deputy CEO & Gen. Counsel
  • Ms. Colleen McMillen
    VP of Communications
  • Andy Ward
    National Sales Director - UK
  • Mr. David Walton DMS (Age 69)
    Chief Commercial Officer
  • Giffin Daughtridge
    Pres of North America Commercial Operations & Global Molecular Solutions

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













LMDX Stock - Frequently Asked Questions

Should I buy or sell LumiraDx stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LumiraDx in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LMDX shares.
View LMDX analyst ratings or view top-rated stocks.

What is LumiraDx's stock price forecast for 2023?

2 analysts have issued 12-month price objectives for LumiraDx's shares. Their LMDX share price forecasts range from $0.80 to $2.70. On average, they anticipate the company's share price to reach $1.45 in the next year. This suggests a possible upside of 570.1% from the stock's current price.
View analysts price targets for LMDX or view top-rated stocks among Wall Street analysts.

How have LMDX shares performed in 2023?

LumiraDx's stock was trading at $0.90 at the start of the year. Since then, LMDX stock has decreased by 76.0% and is now trading at $0.2164.
View the best growth stocks for 2023 here.

Are investors shorting LumiraDx?

LumiraDx saw a increase in short interest in September. As of September 15th, there was short interest totaling 334,100 shares, an increase of 19.5% from the August 31st total of 279,500 shares. Based on an average daily volume of 147,200 shares, the short-interest ratio is currently 2.3 days. Approximately 0.3% of the company's shares are short sold.
View LumiraDx's Short Interest.

When is LumiraDx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our LMDX earnings forecast.

How were LumiraDx's earnings last quarter?

LumiraDx Limited (NASDAQ:LMDX) released its quarterly earnings data on Thursday, August, 24th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.01. The firm had revenue of $21 million for the quarter, compared to the consensus estimate of $21.07 million. During the same quarter in the prior year, the company posted ($0.58) earnings per share.

What is LumiraDx's stock symbol?

LumiraDx trades on the NASDAQ under the ticker symbol "LMDX."

How do I buy shares of LumiraDx?

Shares of LMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is LumiraDx's stock price today?

One share of LMDX stock can currently be purchased for approximately $0.22.

How much money does LumiraDx make?

LumiraDx (NASDAQ:LMDX) has a market capitalization of $68.93 million and generates $254.48 million in revenue each year. The company earns $-447,790,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis.

How many employees does LumiraDx have?

The company employs 1,210 workers across the globe.

How can I contact LumiraDx?

LumiraDx's mailing address is 99 SUMMER STREET SUITE 200, BOSTON MA, 02110. The official website for the company is www.lumiradx.com. The company can be reached via phone at 354-640-0540 or via email at ir@lumiradx.com.

This page (NASDAQ:LMDX) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -